The multiple sclerosis (MS) therapy market continues to evolve, with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choices. The newest entrants (e.g., Zeposia,…
Until recently, FDA-approved treatments for Alzheimer’s disease (AD) were limited to modestly effective symptomatic agents (e.g., donepezil, memantine), but in 2021, Biogen / Eisai’s Aduhelm (…
Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent…
Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval…
Major depressive disorder is a chronic drug-treated condition, and treatment of it is ingrained with generic therapies. However, many of these therapies suffer from shortcomings in efficacy and/or…
Clarivate Epidemiology’s coverage of neuronal ceroid lipofuscinosis (NCL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and accounts for about 20% of cases of acute leukemia in adults. Chemotherapy has remained the backbone of first-line…
Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highly individual, resulting in a complex management landscape. Two core therapeutic approaches are employed: (1)…